Blockchain Registration Transaction Record

Soligenix Achieves 2-Year Vaccine Stability at High Temperatures

Soligenix develops thermostable vaccines stable for 2+ years at 40°C using ThermoVax platform. Breakthrough eliminates cold chain needs for Ebola/Marburg vaccines.

This breakthrough in thermal stability technology addresses one of the biggest challenges in global vaccine distribution—the cold chain requirement that limits access in developing regions and remote areas. By enabling vaccines to remain effective for extended periods at high temperatures, Soligenix's innovation could dramatically improve outbreak response capabilities for deadly viruses like Ebola and Marburg, potentially saving countless lives during future epidemics. The technology also has broader implications for making all types of vaccines more accessible and cost-effective worldwide, representing a fundamental shift in how we approach disease prevention and pandemic preparedness.